Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate.
The effect of low dose (600 mg/day) alpha-tocopheryl nicotinate on serum lipoprotein(a) (Lp(a] concentration was studied in 28 hyperlipidaemic patients. Serum lipids, lipoproteins and apolipoproteins, except for Lp(a), tended to increase after treatment. In particular, the changes in HDL-cholesterol and apo C-II levels were statistically significant. On the other hand, serum Lp(a) levels in all patients decreased significantly after 2 months of treatment. Furthermore, no difference between before and after treatment was observed in the group with initial Lp(a) levels less than 18 mg/dl, whereas Lp(a) concentrations decreased significantly after treatment in the group with levels greater than or equal to 18 mg/dl. The effects of probucol and alpha-tocopheryl nicotinate on serum Lp(a), total cholesterol and HDL-cholesterol were entirely different. Possible mechanisms of alpha-tocopheryl nicotinate on serum Lp(a) and lipoprotein metabolism are discussed.
Noma
A
A
Department of Laboratory Medicine, Gifu University School of Medicine, Japan.
Maeda
S
S
Okuno
M
M
Abe
A
A
Muto
Y
Y
D000328:Adult; D000368:Aged; D053304:Apolipoprotein C-II; D001056:Apolipoproteins C / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D017270:Lipoprotein(a); D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D011341:Probucol / Q000627:therapeutic use; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000627:therapeutic use
D053304:Apolipoprotein C-II; D001056:Apolipoproteins C; D008076:Cholesterol, HDL; D017270:Lipoprotein(a); D008074:Lipoproteins; D009539:Nicotinic Acids; D014810:Vitamin E; C012581:alpha-tocopheryl nicotinate; D002784:Cholesterol; D011341:Probucol